 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced positive preclinical findings published in Frontiers in Immunology regarding the prospect of MN-166 ibudilast as an adjunct treatment for glioblastoma. The publication, entitled Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression, was a collaborative effort between MediciNova and the Cleveland Clinic, led by Tyler Alban doctoral candidate and Dr. Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute, Cleveland Clinic, and Associate Professor, Department of Molecular Medicine at Case Western Reserve University. 